ICER Condemns Monopoly Pricing of Trikafta Despite High Marks for Efficacy
While the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis is indisputable, the Institute for Clinical and [...]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic [...]
ICER Releases Report on Cystic Fibrosis Drugs
The Insitute for Clinical and Economic Review (ICER) released an evidence report on cystic fibrosis treatments. ICER evaluated Vertex Pharmaceuticals' [...]
Advertisement
